You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

NICE backs AZ’ Calquence for chronic lymphocytic leukaemia

The National Institute for Health and Care Excellence has published preliminary guidelines backing use of AstraZeneca’s Calquence (acalabrutinib) as an NHS funded treatment for chronic lymphocytic leukaemia (CLL).